Management for Biotechnology Biot 203b, Spring 2017 Brenda Anderson (Heller), Jon Chilingerian (Heller), Jane Ebert (IBS), Ben Gomes-Casseres (IBS), Jody Hoffer Gittell (Heller), Jim La Creta (IBS), Jean Claude Makolo (National Bureau of Economic Research), Charles Reed (IBS), and Neil Simister (Biology) Wednesday 2-4.50 PM in Rosenstiel 118 Biot 203b introduces life science students to basic business concepts and tools, with an emphasis on the biotechnology and pharmaceutical industries. Course Format: The course will include lectures by distinguished faculty from the International Business School and Heller School for Social Policy and Management. These will allow students a window into the best academic thinking as well as real-life business experience. Learning goals: Students who successfully complete Biot 203 will be better prepared to work in the biotechnology industry whether in a research lab, a start-up, or a larger company. Students will be able to use the language of business and management. They will be able to think critically about management problems and propose solutions based upon principles in accounting, finance, organizational behavior, strategy, project management, and marketing. They will be able to communicate business ideas effectively, both orally and in writing. They will be aware of ethical, societal, and environmental implications of corporate practices and be able to evaluate these factors when making business decisions. Attendance is required. To get the most value from the course, students need to do a lot of work outside of class. I expect students to spend a minimum of 9 hours per week on readings and other information-gathering, and working on the individual and team assignments. Office hours: Neil Simister, Monday 1-2 PM and Thursday 2-3 PM in Bassine 203, ext. 64952, simister@brandeis.edu. IBS faculty office hours in the Sachar International Center and Lemberg Academic Center. Text: Ronald J. Ebert and Ricky W. Griffin, Business Essentials, 8th edition (note, this is not the most recent edition), 2010: Prentice Hall. Cases: Buy readings at the Harvard Business Publishing site: http://cb.hbsp.harvard.edu/cbmp/access/59492628 Electronic resources: You can access the LATTE site with your UNET name and password. Grading will be based on 33% for participation, 33% for assignments, and 34% for final paper. The final presentation will be of a 3-5 page written document that develops one topic you find interesting in the business of biotechnology. Prof. Simister must approve the topic in advance. Learning/other disabilities: If you have a documented disability on record at Brandeis, please talk to Dr. Simister early about any special needs you may have, or any reasonable accommodation you may require. Dr. Simister is hearing-impaired; when you speak to him, you may need to talk more loudly than usual, and you may notice that he looks at your lips for clues to what you say. Academic integrity: Students should be familiar with and must uphold Brandeis policies on academic honesty http://www.brandeis.edu/studentaffairs/srcs/rr/index.html. These include the requirement that all work submitted for credit must be the student's own, except where the contributions of others are explicitly acknowledged or where teamwork is explicitly allowed. Take care to use quote marks and cite direct quotes, and to cite substantial paraphrasing; work may be checked for plagiarism. Management for Biotechnology page 1
Date Class Topic Advance Reading Instructor Jan 18 Jan 25 Feb 1 Feb 8 Feb 15 Accounting Accounting, Continued Organizational Behavior and Leadership Finance Finance, Continued Ebert Ch. 14 Ebert Ch. 14 Ebert Ch.s 8 & 9 Chilingerian, J. The discipline of strategic thinking in healthcare. In Managing and leading in the Allied Health Professions, Ch. 12. Chilingerian, J. Who Has Star Quality? In Consumer-Driven Health Care, Ch. 38. Bollier, D. & Weiss, S., 1991. Merck & Co. Inc. (A). The Business Enterprise Trust 9-991-021. Study questions to be completed before class: 1. What are the stakes for Vagelos and Merck in considering Campbell s idea? 2. What kind of organization is Merck? 3. Should Merck invest in Campbell s idea? 4. If you approve Campbell s proposal and ten other scientists want you to invest in their ideas to find unprofitable cures for other dreadful diseases, are you going to invest in them all? How would you make a decision? Ebert Ch. 15 Ebert Ch. 16 Brenda Anderson Brenda Anderson Jon Chilingerian Jean Claude Makolo Jean Claude Makolo Feb 22 Recess No class Mar 1 Mar 8 Project Management 1 Project Management 2 Ebert Ch. 7 Roberto, M. & Carioggia, G., 2003. Mount Everest, 1996. HBP 303061-PDF-ENG Jim La Creta Jim La Creta Management for Biotechnology page 2
Mar 15 Mar 22 Strategy and Industry Competition Alliance and Acquisition Strategies Porter, M.E., 1996. What is Strategy? go to Brandeis Lib Guides here: http://brandeis.libguides.com/content.p hp?pid=11597&sid=80223, select Business Source Premier, and search by article name. Porter, M.E., 2008. The Five Competitive Forces that Shape Strategy. Business Source Premier, as above Yoffie, D.B. & Wang, Y., 2004. Cola Wars Continue: Coke vs. Pepsi in the Twenty-First Century. HBP 702442- PDF-ENG. Please prepare this case carefully using framework in the article Study questions to be completed before class: 1. How is strategy different from operational efficiency? 2. Be sure you understand Porter s Five Forces model in the second article. 3. What are the important forces in the soft drink industry? Consider this question for two separate segments of the industry: (1) concentrate producers and (2) bottlers. 4. How have these forces affected the industry s profitability? 5. Why do concentrate producers want to integrate vertically into bottling? Additional assignment, time allowing: 6. Apply Porter s Five Forces to one or more segments of the pharmaceutical industry, using info. you find online or your own knowledge of the industry, or input from fellow students. Watkins, M.D. & Matthews, S.G., 2005. Strategic Deal-making at Millennium Pharmaceuticals. HBP 800032-PDF- ENG Gomes-Casseres, B., Alliance Strategy: Managing Beyond the Alliance. http://www.alliancestrategy.com/pdfs/ BGC%20AllianceStrategy%20CriticalEY E04.pdf Ben Gomes- Casseres Ben Gomes- Casseres Management for Biotechnology page 3
Mar 29 Apr 5 Human Resource Management Models of Successful Entrepreneurship Ebert Ch. 10 Gittell, J.H. 2009. High Performance Healthcare, Ch. 1-3. Study questions to be completed before class (1-2 pages only): Business Essentials 1. Consider the HR practices introduced in this chapter (HR planning, job analysis, recruitment, selection, training, performance appraisals, managing diversity, etc.). Choose an organization you have experienced as an employee or frequent customer, and consider how these HR practices work in that organization. What are some strengths of the HR practices in that organization, and some areas for potential improvement? High Performance Healthcare 2. What is relational coordination, and how does it affect strategic performance outcomes in healthcare? 3. Consider some coordination challenges in biotech (coordinating clinical trials, scaling up from testing to production, coordinating the supply chain, etc.). How might relational coordination affect strategic performance outcomes for biotech companies? 4. How would you design HR practices to support relational coordination, by breaking down silos that get in the way? Chapters 2, 3 & 4 in Jeff Timmon's book New Venture Creation, 8th edition. Newland Medical Technologies case. There are suggested questions on which to focus at the beginning. An ebook for this assignment is on McGraw- Hill's ebook website. It includes both the readings and the case. It costs $12.56. You may find it by searching for ISBN # 9781121850552 or under Brandeis University and Charles Reed. It is listed as Course BIOT 203. URL is https://create.mheducation.com/shop/#/c atalog/details/?isbn=9781121850552 Jody Hoffer Gittell Charles Reed Apr 12 Recess No class Management for Biotechnology page 4
Apr 19 Brandeis Monday No class Apr 26 Essentials of Marketing Ebert Ch. 11 Gourville, J.T., 1999. Biopure Corp.. HBP 598150-PDF-ENG Preparation for class: 1. Read chapter 11 and Biopure case. 2. Prepare answers for questions for discussion in class (listed below). 3. In class, hand in your assessment for Question 1 (paragraph describing potential human market and paragraphs describing potential animal market, plus an attempt to quantify the size of each market, including numbers for sales and price). Jane Ebert May 3 Student Presentations Questions: 1. How do you assess BioPure s potential in the human market? The animal market? 2. What are the biggest obstacles to Biopure s success in the human market? The animal market? 3. How might Oxyglobin be a threat to Hemopure? How might it be an asset to Hemopure? 4. What should Biopure do regarding the commercial release of Oxyglobin? If they release, what price should they set? How should it be distributed? Neil Simister Management for Biotechnology page 5